Apixaban + aspirin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Atrial Fibrillation
Conditions
Atrial Fibrillation, Stroke
Trial Timeline
May 1, 2015 → Nov 3, 2023
NCT ID
NCT01938248About Apixaban + aspirin
Apixaban + aspirin is a approved stage product being developed by Pfizer for Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT01938248. Target conditions include Atrial Fibrillation, Stroke.
What happened to similar drugs?
20 of 20 similar drugs in Atrial Fibrillation were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01938248 | Approved | Completed |
Competing Products
20 competing products in Atrial Fibrillation